News | Coronavirus (COVID-19) | February 24, 2021

Cardiovascular Admissions Reduced in U.K. During a Second Wave of COVID-19

Evidence continues to mount showing more than a third of U.K. patients are ignoring heart attack and acute heart failure symptoms

UK hospU.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms.ital admissions for heart attacks and heart failure have been reduced by COVID-19 as people fear going to hospitals. Getty Images #COVIDUK #COVID19

U.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms. Getty Images


February 24, 2021 — A study of admissions for acute myocardial infarction (AMI) and heart failure (HF) in the U.K. decreased by 41% and 34% respectively during the second wave of the COVID-19 panademic in the fall of 2020. The first wave in March 2020 saw a 54% decrease in admissions.[1]

The first wave of the COVID-19 pandemic was associated with a decline in admissions for cardiovascular disease. Many cardiologists remain concerned that the decline was related to care-seeking behavior rather than a change in incidence. These investigators used national U.K. databases to determine whether the second lockdown in the U.K. was accompanied by a similar decline in admissions.

In a sample of “rapid reporting” hospitals, the researchers identified 62,683 admissions for heart failure and acute myocardial infarction (AMI) between November 1, 2018, and November 17, 2020. During the first lockdown, which began in March 2020, daily hospitalizations for heart failure and AMI declined by 54%. The rates began to increase during April and almost returned to baseline by June. Beginning with the second lockdown in October 2020, admissions again declined, with decreases of 41% in hospitalizations for heart failure and 34% for AMI. For context, the admission rates for 2018 varied little from the 2019 rates.

The authors wrote that despite an initial recovery in admissions with HF and MI, the latter part of 2020 has witnessed a second decline in people hospitalized with these conditions, which pre-dated the onset of the second national lockdown in the United Kingdom. The second dip appears of similar magnitude to that of the first and signals that the public are fearful of attending hospitals despite having medical emergencies, and that this varies over time, possibly relating to numbers of cases and social mandates. This is important because earlier work from the United Kingdom described how delays to seeking help were temporally related to an inflation in deaths from a range of acute cardiovascular diseases. The authors said the decline in admissions requires clear public messaging to prevent further unintended consequences with increased deaths and poor outcomes due to delays in cardiac care.

 

Related Cardiology COVID Content:

VIDEO: Where Have all the STEMI Cases Gone Amid COVID-19? — Interview with Thomas Maddox, M.D.

Rapid Drop in Heart Attacks and Stroke at Hospitals Concerns ACC 

VIDEO: Patients Fear COVID More than Heart Attacks — Interview with Cindy Grines, M.D.

SCAI Study Shows COVID Fears Continue to Cause Americans to Avoid Doctor Visits

The Long-term Cardiovascular Impact of COVID-19

Cardiologists Should Prioritize Influenza Vaccination Amidst COVID-19 Pandemic

Find more cardiology related COVID-19 content

 

Reference:

1. Jianhua Wu, Mamas A. Mamas, Mar A. de Belder, John E.Deanfield, Chris P.Gale. Second decline in admissions with heart failure and myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol. Published online 2021 Jan 12. https://doi.org/10.1016/j.jacc.2020.12.039.


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now